WW International, Inc. (WW) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. WW International, Inc. emerged from Chapter 11 bankruptcy on June 24, 2025, applying "fresh start" accounting. Consequently, financial results are presented as "Successor" (post-emergence) and "Predecessor" (pre-emergence). The company operates two primary segments: Behavioral (digital subscriptions and workshops) and Clinical (clinical product offerings combined with digital subscriptions). Following the CEO's departure in March 2026, the company is led by an Interim Office of the Chief Executive.
Key Financial Metrics (Successor Period)
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue, Net | $162.3 million | $330.6 million |
| Gross Profit | $114.1 million | $232.8 million |
| Gross Margin | 70.3% | 70.4% |
| Operating Income (Loss) | $9.5 million | ($21.0 million) |
| Net Income (Loss) | $14.1 million | ($37.9 million) |
| Diluted EPS | $1.41 | ($3.79) |
| Cash and Cash Equivalents | $101.5 million | $101.5 million (as of June 30) |
| Long-Term Debt (Net) | $424.0 million | $424.0 million (as of June 30) |
| Operating Cash Flow | Filing text does not provide a clear value for the three-month period. | ($9.3 million) |
Material Changes vs. Prior Comparable Period
- Revenue Mix Shift: Total subscription revenue declined 14.1% year-over-year (Q2 2026 vs. Combined Q2 2025). This was driven by a 22.7% decline in Behavioral Subscription Revenue due to lower incoming subscribers and secular headwinds. Conversely, Clinical Subscription Revenue increased 30.4%, driven by demand for GLP-1 options and the Med+ membership tier.
- Subscriber Trends: Total incoming subscribers decreased 22.6% year-over-year. Behavioral incoming subscribers fell 25.4%, while Clinical incoming subscribers rose 45.9%.
- Debt Restructuring: Post-emergence, the company refinanced prepetition debt into a New Term Loan Facility. In May 2026, the company voluntarily prepaid $14.6 million of principal at 68.5% of par, recording a $4.6 million gain on extinguishment of debt. In June 2026, a mandatory cash sweep prepayment of $26.8 million was made.
- One-Time Costs: The quarter included $3.8 million in executive-related one-time costs associated with the CEO transition.
Guidance, Outlook, and Risks
- Liquidity: The company holds $101.5 million in unrestricted cash and does not foresee needing additional liquidity sources in the next 12 months. However, the credit agreement requires mandatory prepayments of unrestricted cash exceeding $100 million.
- Outlook: Management notes that while the Clinical business is growing, it has not yet offset declines in the Behavioral business. The company faces significant competition from GLP-1 medications and new market entrants.
- Risks:
- Leadership Transition: The company is searching for a permanent CEO; failure to appoint one timely could disrupt operations.
- Asset Impairment: The Behavioral reporting unit and Trade Name intangible asset are identified as "at risk" for impairment, with fair value exceeding carrying value by less than 10%.
- Technology: Risks related to cyber-attacks and system failures remain material.
Investor Verification Checklist
- Verify the sustainability of the Clinical segment growth against the continued decline in the core Behavioral segment.
- Monitor the cash sweep covenant requirements, as cash balances near the $100 million threshold could force further debt prepayments.
- Assess the timeline and impact of the CEO search on strategic execution.
- Review future goodwill and intangible asset impairment tests, given the current "at risk" status of the Behavioral unit and Trade Name.
- Confirm the trajectory of operating cash flows, which were negative ($9.3 million) for the six-month period.